SB 188 – Connecticut
Introduced: 2022 Status: Inactive / Dead
AN ACT REQUIRING BRAND NAME PRESCRIPTION DRUG MANUFACTURERS TO PROVIDE SAMPLES OF BRAND NAME DRUGS TO GENERIC PRESCRIPTION DRUG MANUFACTURERS. To promote competition in the prescription drug market by allowing developers of generic drugs and …
SB 241 (see companion bill HB 2529) – Texas
Introduced: 2023 Status: Enacted
Relating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.
SB 764 – Oregon
Introduced: 2021 Status: Inactive / Dead
Provides that court must presume that resolution agreement that ends dispute over alleged infringement of patent or violation of other protection for protected drug has anticompetitive effects if alleged infringer receives item of value as …
SF 184 – Minnesota
Introduced: 2021 Status: Inactive / Dead
Affordable drugs act access preservation
SP 432 (see companion bill LD 1280) – Maine
Introduced: 2017 Status: Enacted Year Enacted: 2018
AN ACT REGARDING GENERIC DRUG PRICING. This bill amends the Maine Pharmacy Act to require that a drug distributed in this State must be made available for sale in this State to a person seeking …